[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CA2000479A1 - Vasopermeability-enhancing conjugates - Google Patents

Vasopermeability-enhancing conjugates

Info

Publication number
CA2000479A1
CA2000479A1 CA2000479A CA2000479A CA2000479A1 CA 2000479 A1 CA2000479 A1 CA 2000479A1 CA 2000479 A CA2000479 A CA 2000479A CA 2000479 A CA2000479 A CA 2000479A CA 2000479 A1 CA2000479 A1 CA 2000479A1
Authority
CA
Canada
Prior art keywords
species
vasoactive
disclosed
agent
linked
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2000479A
Other languages
French (fr)
Other versions
CA2000479C (en
Inventor
Alan L. Epstein
M. Michael Glovsky
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Southern California USC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2000479A1 publication Critical patent/CA2000479A1/en
Application granted granted Critical
Publication of CA2000479C publication Critical patent/CA2000479C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Conjugates having a clinically useful delivery vehicle linked to a biologically active species which acts to increase vascular permeability and expand blood volume at or in proximity to the tumor site are disclosed. the vehicle-linked species may be, for example, a vasoactive agent, a substance that recruits or amplifies a vasoactive species, a drug, or a pharmaceutical compound. Suitable biological species comprises peptides, lipids, carbohydrates, or their derivatives. Chemical or recombinant DNA methods suitable for linking the species to the vehicles are indicated. A therapy is disclosed which comprises administering the vasoactive conjugate and delivering a diagnostic agent or a therapeutic agent at an optimal time thereafter, when tumor vasculature is maximally affected.
CA002000479A 1988-10-11 1989-10-11 Vasopermeability-enhancing conjugates Expired - Lifetime CA2000479C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25551388A 1988-10-11 1988-10-11
US255,513 1988-10-11

Publications (2)

Publication Number Publication Date
CA2000479A1 true CA2000479A1 (en) 1990-04-11
CA2000479C CA2000479C (en) 2000-06-20

Family

ID=22968671

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002000479A Expired - Lifetime CA2000479C (en) 1988-10-11 1989-10-11 Vasopermeability-enhancing conjugates

Country Status (1)

Country Link
CA (1) CA2000479C (en)

Also Published As

Publication number Publication date
CA2000479C (en) 2000-06-20

Similar Documents

Publication Publication Date Title
EP0438497A4 (en) Vasopermeability-enhancing conjugates
US5543389A (en) Covalent polar lipid-peptide conjugates for use in salves
EP0861667A3 (en) Particulate agents
EP2347770B1 (en) Process for producing an injectable pharmaceutical preparation
CA2064689A1 (en) Stabilized protein or peptide conjugates
DE69534676T2 (en) Oral administration of chemically modified proteins
AU608264B2 (en) Delivery vehicles with amphiphile-associated active ingredient
Fiume et al. Drug targeting in antiviral chemotherapy: A chemically stable conjugate of 9-β-d-arabinofuranosyl-adenine 5'-monophosphate with lactosaminated albumin accomplishes a selective delivery of the drug to liver cells
DE60032255T2 (en) POLYMER-STABILIZED NEUROPEPTIDES
EP0329184A3 (en) Antimers and antimeric conjugation
WO1988006045A3 (en) Device for the removal of active substances locally applied against solid tumors
WO1999024074A3 (en) Novel conjugates of opioids and endogenous carriers
CA2182228A1 (en) Codrugs as a method of controlled drug delivery
CA2184242A1 (en) Drug Targeting System, Method for Preparing Same and Its Use
WO1999048536A3 (en) Delivery of long lasting therapeutic agents by forming covalent attachments in vivo
CA2295177A1 (en) Drug targeting system, method of its preparation and its use
IL97411A (en) Pharmaceutical formulations comprising hapten-modified diagnostic or therapeutic agents
WO1992005866A3 (en) Efficient microcapsule preparation and method of use
WO1999056723A3 (en) Hemoglobine-haptoglobin complexes for targeted drug delivery
EP0335133A3 (en) Drug delivery using pulmonary surfactant fo facilitate absorption
WO1992004916A3 (en) Particulate agents
CA2000479A1 (en) Vasopermeability-enhancing conjugates
CA2073554A1 (en) Water-soluble composition for sustained-release
JPH06293631A (en) Drug delivery system using keratin dydrolyzate as carrier
JPH04501705A (en) Use of fibrinolytic agents for combined treatment of tumors

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry